Results 21 to 30 of about 832,259 (254)

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

, 2023
Natural killer (NK) cells are cytotoxic lymphocytes that are critical for the innate immune system. Engineering NK cells with chimeric antigen receptors (CARs) allows CAR-NK cells to target tumor antigens more effectively.
John Sienkiewicz, Hua Zhou, Lijun Wu, Yanwei Huang, Shiming Zhang, Jinying Sun, Hizkia Harto, Shirley Xu, Vita Golubovskaya, Robert Berahovich   +9 more
core   +1 more source

KIR-Based Inhibitory CARs Overcome CAR-NK Cell Trogocytosis-Mediated Fratricide and Tumor Escape [PDF]

, 2022
Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen receptor (CAR) activation in natural killer (NK) cells promoted ...
Rezvan, Ali, Shpall, Elizabeth J, Kerbauy, Lucila N, Bover, Laura, Biederstädt, Alexander, Mendt, Mayela, Liu, Bin, Uprety, Nadima, Ang, Sonny, Lin, Paul, Melo Garcia, Luciana, Ensley, Emily, Rezvani, Katayoun, Li, Li, Varadarajan, Navin, Guo, Xingliang, Basar, Rafet, Laskowski, Tamara J, Marin, David, Liu, Enli, Moyes, Judy S, Li, Ye, Champlin, Richard E, Wang, Guohui, Banerjee, Pinaki P, Daher, May, Shanley, Mayra, Chen, Ken, Fathi, Mohsen, Muniz-Feliciano, Luis, Rafei, Hind, Acharya, Sunil   +31 more
core   +1 more source

IPSC-derived CAR-NK cells for cancer immunotherapy

, 2023
Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies.
Guozhu Xie, Ryohichi Sugimura, Xin Dong, Dong, Xin, Xie, Guozhu, Lin, Xiaotong, Zishen Liu, Sun, Yao, Sugimura, Ryohichi, Xiaotong Lin, Liu, Zishen, Yao Sun   +11 more
core   +1 more source

Kir-Based Inhibitory Cars Overcome Car-Nk Cell Trogocytosis-Mediated Fratricide and Tumor Escape [PDF]

, 2023
Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen receptor (CAR) activation in natural killer (NK) cells promoted the ...
LI, YE NMN
core   +1 more source

Current Progress of CAR-NK Therapy in Cancer Treatment

, 2022
CD8+ T cells and natural killer (NK) cells eliminate target cells through the release of lytic granules and Fas ligand (FasL)-induced target cell apoptosis.
Li, Fengqi, Chunjing Feng, Zhaojun Pang, Mu, Xin, Pang, Zhaojun, Feng, Chunjing, Zhongyi Wang, Wang, Zhongyi, Fengqi Li, Xin Mu   +9 more
core   +1 more source

Design of NKG2D-based CAR-NK Cells Targeting Solid Tumors [PDF]

, 2023
Chimeric Antigen Receptor (CAR) engineered NK cells have been shown to enhance the activities of NK cells against cancer in both preclinical and clinical studies.
Wu, Lujing
core  

Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo

Frontiers in Immunology, 2023
IntroductionNatural killer 92 (NK-92) cells are an attractive therapeutic approach as alternative chimeric antigen receptor (CAR) carriers, different from T cells, once they can be used in the allogeneic setting. The modest in vivo outcomes observed with
Renata Nacasaki Silvestre, Jiri Eitler, Jiri Eitler, Julia Teixeira Cottas de Azevedo, Mariane Cariati Tirapelle, Daianne Maciely Carvalho Fantacini, Lucas Eduardo Botelho de Souza, Kamilla Swiech, Dimas Tadeu Covas, Rodrigo T. Calado, Paola Ortiz Montero, Paola Ortiz Montero, Kelen Cristina Ribeiro Malmegrim, Kelen Cristina Ribeiro Malmegrim, Marxa L. Figueiredo, Torsten Tonn, Torsten Tonn, Torsten Tonn, Virginia Picanço-Castro   +18 more
doaj   +1 more source

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Journal of Hematology & Oncology, 2020
Natural killer (NK) cells are a critical component of the innate immune system. Chimeric antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding antigens, creating major opportunities in the fight against cancer.
Ahmet Yilmaz, Hanwei Cui, Michael A. Caligiuri, Jianhua Yu   +3 more
doaj   +1 more source

RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy [PDF]

, 2021
The tumor microenvironment (TME) is greatly multifaceted and immune escape is an imperative attribute of tumors fostering tumor progression and metastasis.
Ali Hassanzadeh, Max Stanley Chartrand, Alaa S. Al-Awad, Alexander Markov, Yulianna Ivanovna Enina, Walid Kamal Abdelbasset, Mahnaz Mahmoodi, Heshu Sulaiman Rahman, Mostafa Jarahian, Mahboubeh Yazdanifar, Faroogh Marofi   +10 more
core   +1 more source

Directing CAR NK Cells via the Metabolic Incorporation of CAR Ligands into Malignant Cell Glycans

, 2022
The abundance of sialic acid-containing glycans in the glycocalyx of malignant cells enables immune evasion. Here, we leverage the biosynthetic pathways that permit pervasive sialylation to incorporate a chimeric antigen receptor (CAR) ligand into ...
Patrick A. Ross (12709860), Mark P. Farrell (12709863), Kathia Antillon (12709857)   +2 more
core   +1 more source